JAMES JEN KIN: Open Payments
NPI 1548238819 · LONG BEACH, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$793 in 33 payments from 9 companies in 2025. Trend: 2023 $3,477 · 2024 $3,773 · 2025 $793
Food & beverage: $793
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 6 | $161 |
| Vanda Pharmaceuticals Inc. | 6 | $124 |
| Neurocrine BioSciences, Inc. | 4 | $114 |
| ABBVIE INC. | 4 | $101 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $95 |
| Otsuka America Pharmaceutical, Inc. | 3 | $65 |
| Alkermes, Inc. | 3 | $63 |
| Teva Pharmaceuticals USA, Inc. | 2 | $44 |
| Lundbeck LLC | 1 | $26 |
Products named: SPRAVATO, FANAPT, INGREZZA, VRAYLAR, CAPLYTA, REXULTI, ARISTADA, AUSTEDO XR.
Industry payments across CA — which companies pay providers there.
